356 related articles for article (PubMed ID: 17875698)
1. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
2. CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.
Sun T; Gianino SM; Jackson E; Piwnica-Worms D; Gutmann DH; Rubin JB
J Neuroimmunol; 2010 Jul; 224(1-2):108-13. PubMed ID: 20554030
[TBL] [Abstract][Full Text] [Related]
3. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
4. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
[TBL] [Abstract][Full Text] [Related]
5. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.
Solga AC; Pong WW; Kim KY; Cimino PJ; Toonen JA; Walker J; Wylie T; Magrini V; Griffith M; Griffith OL; Ly A; Ellisman MH; Mardis ER; Gutmann DH
Neoplasia; 2015 Oct; 17(10):776-88. PubMed ID: 26585233
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
Warrington NM; Gianino SM; Jackson E; Goldhoff P; Garbow JR; Piwnica-Worms D; Gutmann DH; Rubin JB
Cancer Res; 2010 Jul; 70(14):5717-27. PubMed ID: 20551058
[TBL] [Abstract][Full Text] [Related]
7. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.
Solga AC; Gianino SM; Gutmann DH
Oncogene; 2014 Jan; 33(3):289-99. PubMed ID: 23318450
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
9. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
10. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Bajenaru ML; Hernandez MR; Perry A; Zhu Y; Parada LF; Garbow JR; Gutmann DH
Cancer Res; 2003 Dec; 63(24):8573-7. PubMed ID: 14695164
[TBL] [Abstract][Full Text] [Related]
11. Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1.
Assunto A; Ferrara U; De Luca A; Pivonello C; Lombardo L; Piscitelli A; Tortora C; Pinna V; Daniele P; Pivonello R; Russo MG; Limongelli G; Colao A; Tartaglia M; Strisciuglio P; Melis D
Orphanet J Rare Dis; 2019 Nov; 14(1):261. PubMed ID: 31730495
[TBL] [Abstract][Full Text] [Related]
12. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
Rodriguez FJ; Ligon AH; Horkayne-Szakaly I; Rushing EJ; Ligon KL; Vena N; Garcia DI; Cameron JD; Eberhart CG
J Neuropathol Exp Neurol; 2012 Sep; 71(9):789-94. PubMed ID: 22892521
[TBL] [Abstract][Full Text] [Related]
13. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma.
Kim KY; Ju WK; Hegedus B; Gutmann DH; Ellisman MH
Neuroscience; 2010 Sep; 170(1):178-88. PubMed ID: 20600672
[TBL] [Abstract][Full Text] [Related]
14. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
Pong WW; Higer SB; Gianino SM; Emnett RJ; Gutmann DH
Ann Neurol; 2013 Feb; 73(2):303-8. PubMed ID: 23424002
[TBL] [Abstract][Full Text] [Related]
15. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
18. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromin in the brain.
Gutmann DH
J Child Neurol; 2002 Aug; 17(8):592-601; discussion 602-4, 646-51. PubMed ID: 12403558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
